骨与软组织肉瘤肺转移灶体积倍增时间与转移切除术后新发转移及生存的关联
该回顾性研究纳入40例骨或软组织肉瘤患者,基于两次术前CT半自动体积分割计算肺转移灶体积倍增时间(VDT)。结果显示VDT较短者术后新发转移更多、生存更差;VDT<140天为无复发生存独立预测因子,VDT<50天为总生存独立预测因子。
要点
- 肺转移灶VDT较短提示术后新发转移风险高、生存差。
- VDT<140天与更差无复发生存独立相关(HR 4.22)。
- VDT<50天与更差总生存独立相关(HR 8.60)。
核心结论
- 骨与软组织肉瘤患者肺转移灶VDT较短与转移切除术后新发转移及更差总生存独立相关。
研究设计与样本
- 对两次CT上的肺转移灶进行半自动体积分割并计算VDT,比较有无术后新发转移患者的VDT,采用Cox比例风险回归分析无复发生存(RFS)和总生存(OS)的危险因素。
诊断标准与关键数值
- 术后新发转移患者的中位VDT为56天,无新发转移患者为140天(p=.002)。
- 23例新发转移患者中仅4例VDT≥140天。
- 多因素分析中,年龄较大(HR 1.06,p=.004)、女性(HR 2.80,p=.03)和VDT<140天(HR 4.22,p=.01)是更差RFS的独立预测因子。
- 多因素分析中,仅年龄较大(HR 1.17,p=.005)和VDT<50天(HR 8.60,p=.02)是更差OS的独立预测因子。
- VDT<140天患者(27例中10例死亡)的OS显著差于VDT≥140天患者(13例中无死亡)(p=.01)。
临床应用与阅片要点
- 肺结节VDT可考虑用于肺转移切除术的患者选择和术后管理。
局限性
- 回顾性研究,样本量较小(40例),可能限制结论的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Pulmonary metastases of bone and soft-tissue sarcoma are common and have a high recurrence rate after metastasectomy. Factors associated with postmetastasectomy recurrence are not well studied. OBJECTIVE. The purpose of this study was to investigate the association of the volume doubling time (VDT) of pulmonary metastases with the subsequent development of new pulmonary nodules and survival after metastasectomy in patients with bone or soft-tissue sarcoma. METHODS. This retrospective study included patients with bone or soft-tissue sarcoma who, between January 2010 and December 2020, underwent first complete metastasectomy of pulmonary nodules visualized on two sequential preoperative CT scans. Semiautomatic volumetric segmentation of the pulmonary metastases was performed on the two CT scans, and VDTs were calculated. VDT was compared between patients with and without subsequent new metastases after metastasectomy. Cox proportional hazards regression analyses were performed to determine risk factors for recurrence-free survival (RFS) after metastasectomy and for postmetastasectomy overall survival (OS). RESULTS. Forty patients (21 women, 19 men; mean age, 51.1 ± 14.3 [SD] years) were included. Of these patients, 23 (57.5%) developed new metastatic nodules after metastasectomy, and 10 (25.0%) died during follow-up. Median VDT was shorter in patients with, versus those without, new metastases after metastasectomy (56 vs 140 days, p = .002). Only four of 23 patients with new metastases had VDT of 140 days or more. In multivariable analysis, older age (hazard ratio [HR], 1.06; p = .004), female sex (HR, 2.80; p = .03), and VDT less than 140 days (HR, 4.22; p = .01) were independent predictors of worse RFS. Also in multivariable analysis, only older age (HR, 1.17; p = .005) and VDT less than 50 days (HR, 8.60; p = .02) were independent predictors of worse OS. OS was significantly worse in patients with VDT less than 140 days (10 deaths among 27 patients) than in patients with VDT of 140 days or more (no deaths in 13 patients) (p = .01). CONCLUSION. In patients with bone and soft-tissue sarcoma, shorter VDT of pulmonary metastases is independently associated with subsequent new metastases after metastasectomy and worse OS. CLINICAL IMPACT. VDT of pulmonary nodules may be considered in patient selection for pulmonary metastasectomy and in postoperative patient management.
引用
- Ahn, Lee, Kim, et al. Volume Doubling Times of Pulmonary Metastases in Patients With Bone and Soft-Tissue Sarcomas: Associations With Subsequent New Metastases and Survival After Metastasectomy. AJR Am J Roentgenol. 2021. PMID: 34730372. doi:10.2214/AJR.21.26859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。